Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey | Zendy

Marion Gauthier | Zendy; Florence CanouïPoitrine | Zendy; Esther Guéry | Zendy; Dominique Desvaux | Zendy; Sophie Hüe | Zendy; Guillaume Canaud | Zendy; Thomas Stehlé | Zendy; Philippe Lang | Zendy; Tomek Kofman | Zendy; Philippe Grimbert | Zendy; Marie Matig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey

Author(s) -

Marion Gauthier,

Florence CanouïPoitrine,

Esther Guéry,

Dominique Desvaux,

Sophie Hüe,

Guillaume Canaud,

Thomas Stehlé,

Philippe Lang,

Tomek Kofman,

Philippe Grimbert,

Marie Matig

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx353

Subject(s) - medicine , cohort , antibody , kidney transplantation , kidney transplant , donor specific antibodies , cohort study , kidney , anticardiolipin antibodies , renal function , immunology

In kidney transplant recipients, anticardiolipin (ACL) antibodies without antiphospholipid syndrome (APS) are found in up to 38% of patients and could be associated with thrombotic events (TEs). However, the prognostic role of ACL regarding kidney transplant and patients outcomes have still not been well defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research